After a long and winding road, the FDA has at last given Forest Laboratories Inc. the green light to market Daliresp (roflumilast) in the U.S. to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of such flare-ups, which may include breathlessness, chronic cough and excessive production of phlegm leading to medical intervention, including hospitalization.